Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Nucleic Acids Research|March 18, 2020
Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forksJohn J Krais, Neil JohnsonCancer Research|August 5, 2020
BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with TumorigenesisJohn J Krais, Neil JohnsonPlos One|October 8, 2013
Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapyJohn J Krais, Olivier De Crescenzo, Roger G HarrisonGenome Medicine|May 26, 2025
DNA repair and the contribution to chemotherapy resistanceKsenija Nesic, Phoebe Parker, Elizabeth M Swisher, et al.Nature Communications|August 19, 2021
RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damageJohn J Krais, Yifan Wang, Pooja Patel, et al.Cancer Investigation|October 3, 2013
Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculatureBrent D Van Rite, John J Krais, Mohamad Cherry, et al.Cancer Biology & Therapy|April 2, 2019
Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibitionRashid Gabbasov, I Daniel Benrubi, Shane W O'Brien, et al.Nanotechnology|August 27, 2013
Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapyLuís F F Neves, John J Krais, Brent D Van Rite, et al.Cancer Research|March 28, 2020
RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null CancersJohn J Krais, Yifan Wang, Andrea J Bernhardy, et al.Molecular Cancer Therapeutics|May 20, 2017
Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and CyclophosphamideJohn J Krais, Needa Virani, Patrick H McKernan, et al.Pageof 3